Navigation Links
A new class of anti-inflammatory drugs
Date:12/10/2008

This release is available in German.

In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices. However, had they been tested using today's stringent criteria, many of these drugs would not have passed the clinical trial stage, due to the potential risks and side effects they entail. This suggests the need for more innovative thinking in this area of drug therapy. One such new approach has been developed in Manfred Schubert-Zsilavecz's laboratory at the Goethe University, using chemical substances belonging to the dual mPGES-1/5-LO-Inhibitors. Oliver Werz's group at Tbingen has characterized the substances at the molecular/pharmacological level. Their research results now form the basis of a joint patent application, and a publication in the renowned "Journal of Medicinal Chemistry" (Koeberle et al, J Med Chem (2008), Nov 19. [Epub ahead of print]).

Aspirin and the related NSAR drugs act on the arachidonic acid biosynthesis cascade, which plays a central role in the onset of pain and inflammation. They thus prevent the synthesis of specific prostaglandins, which are essential for vital bodily functions. When the drugs are taken over a long period of time, the unselective inhibition of this essential pathway may result in unwanted side effects on the gastrointestinal tract and the cardiovascular system. As Schubert-Zsilavecz explains: "By comparison, our class of drugs/substances acts on a later stage in the arachidonate cascade, and is more selective. We therefore can expect it to have considerably fewer side effects."

A further advantage of this new class of drugs is that they not only specifically target the biosynthesis of prostaglandin, but also of leukotrienes, which are metabolites in the second important branch of the arachidonate cascade and play a central role in allergic and inflammatory reactions. This double attack promises more effective results for these new substances.

Gerd Geisslinger, Speaker of the LiFF-Initiative and President of the Center for Drug Research, Development and Safety (ZAFES) explains: "This is a most important success for our newly established Lipid Signalling Research Centre, which was established only a short time ago under the LOEWE initiative, funding research in the German state Hesse."


'/>"/>

Contact: Manfred Schubert-Zsilavecz
Schubert-Zsilavecz@pharmchem.uni-frankfurt.de
49-069-798-29339
Goethe University Frankfurt
Source:Eurekalert  

Related medicine news :

1. Popular class of diabetes drugs doubles risk of fractures in women
2. Triple-S Management Corporation Announces Conversion of Class A Shares and Commencement of Class B Stock Repurchase Program
3. Frost & Sullivan Recognises Best-in-Class Innovators
4. On Staying Alives 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador
5. Scientists at CSHL uncover new RNA processing mechanism and a new class of small RNAs
6. Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff
7. Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation
8. Alex Rodriguez, Ryan Howard and Terry Francona to Headline David Ortiz Celebrity Golf Classic
9. Avandias Heart Risk Higher Than Others in Its Class
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit on Behalf of Investors of PharmaNet Development Group, Inc.
11. OmniVision Unveils 1.8 mm, Low Power Medical Sensor With Best-in-Class Low Light Performance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new class of anti-inflammatory drugs
(Date:4/29/2016)... ... 29, 2016 , ... Our bodies are bombarded daily by environmental and lifestyle ... these stressors is to adopt a more healthful diet, but too many people think ... certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment of ... invited to be a featured speaker at the Texas Society of the American College ... , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will speak ...
(Date:4/29/2016)... ... 29, 2016 , ... The Gluten-Free Certification Program (GFCP), in ... the launch of the GFCP Scoop in response to consumer demand ... the GFCP Scoop site is to keep the gluten-free community updated ...
(Date:4/29/2016)... Beverly Hills, CA (PRWEB) , ... April 29, 2016 , ... ... distributor of devices and products for the head and neck/ear, nose and throat specialty, ... Safety Device , The KOTLER NASAL AIRWAY™ is a newly patented safety ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 2016 At the Sachs CEO ... a Phase 2 clinical study of its lead drug ... cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase ... Germany and France . ... the time of surgery. "Despite advances in cochlear implant ...
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. ... a management presentation at the Deutsche Bank 41 st ... 2:50 p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas . ... hour after conclusion of the live event and accessible at ...
(Date:4/26/2016)... April 27, 2016 Research and ... Molecular Diagnostics Market 2016-2020" report to their offering. ... ,The global molecular diagnostics market is projected to grow ... Molecular diagnostics is a technique that involves ... molecular level to detect changes in biochemical pathways. The ...
Breaking Medicine Technology: